TOTAL VOLUME:
$134b
24H VOL:
$103,397,351
24H TRANSACTIONS:
2,388,728,490
OPEN INTEREST:
$1,410,176,180
399,592
Markets across
30,097
events
MATCHED EVENTS:
2,622
PLATFORM COVERAGE:
5
Polymarket:
39%
VS.
Kalshi:
61%
FDA approves Merck's Welireg + Keytruda or Keytruda Qlex?
- Polymarket
FDA approves Merck's Welireg + Keytruda or Keytruda Qlex? - Polymarket
1W
News
Positive
Negative
Neutral
Hover marker for details
Vol.
·
Resolved Jun 16, 2026
Closed: Jun 18, 8:00 PM EST
Polymarket
FDA approves Merck's Welireg + Keytruda or Keytruda Qlex?
Description
As of market creation, the FDA's expected decision date for the specified application is June 19, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Merck's Welireg + Keytruda or Keytruda Qlex as a treatment for adjuvant treatment of clear cell renal cell carcinoma following nephrectomy by July 3, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Polymarket
As of market creation, the FDA's expected decision date for the specified application is June 19, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Merck's Welireg + Keytruda or Keytruda Qlex as a treatment for adjuvant treatment of clear cell renal cell carcinoma following nephrectomy by July 3, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Frequently asked questions
Prediction market odds on Polymarket reflect real-money trader conviction and often diverge from traditional analyst consensus. While Wall Street equity analysts and pharma research firms publish approval probability estimates based on trial data and regulatory precedent, prediction markets aggregate dispersed information from traders with direct market exposure. Analyst forecasts tend to lag market repricing following clinical readouts or FDA guidance letters. Comparing Polymarket odds to published analyst estimates reveals whether the market is pricing in more optimism or skepticism than the consensus view, helping investors identify potential mispricing.
On Polymarket, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. On Polymarket, this event is priced as a binary outcome contract where traders buy and sell shares representing approval or non-approval. The current implied probability reflects the last traded price, with higher prices indicating stronger market belief in FDA approval. Polymarket's automated market maker model allows continuous trading and price discovery. Traders can enter or exit positions at any time before the Jun 19, 2026 resolution date. Volume and bid-ask spreads on Polymarket indicate liquidity and conviction; wider spreads suggest uncertainty or lower participation around this specific Merck combination therapy outcome.
This market resolves on Jun 19, 2026, giving traders approximately 18 months to position ahead of potential FDA action. Resolution hinges on whether Merck receives formal FDA approval for Welireg in combination with either Keytruda or Keytruda Qlex by that deadline. The outcome is binary: approval triggers a YES resolution, while rejection, withdrawal, or failure to receive approval by the end date triggers NO. Traders should monitor FDA meeting minutes, clinical trial announcements, and regulatory correspondence to anticipate the resolution trigger.
Key catalysts include Phase 3 trial readouts demonstrating efficacy and safety of the Welireg combination, FDA Breakthrough Therapy or Priority Review designations, and advisory committee meeting outcomes. Competitive approvals of similar renal cell carcinoma or oncology combinations could shift market expectations. Regulatory guidance letters or Complete Response Letters from the FDA would trigger sharp repricing. Clinical safety signals or manufacturing delays would pressure odds downward. Merck earnings calls and investor conferences often contain approval timeline updates. Broader pharma sector sentiment and FDA staffing changes also influence trader positioning on this outcome.
